Hematologic Oncology | Specialty

FDA Accepts Application for Zanubrutinib in Waldenström Macroglobulinemia

February 17th 2021

February 17, 2021 — The FDA has accepted a supplemental new drug application of zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL

February 17th 2021

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia

February 17th 2021

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Chronic Lymphocytic Leukemia Treatment Considerations 

February 17th 2021

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Dr. Verstovsek on the Use of Luspatercept to Treat Anemia Associated With Myelofibrosis

February 16th 2021

Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.

Targeted Therapies Reign in the Frontline Treatment of CLL

February 16th 2021

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL

February 16th 2021

CAR T-cell therapy has shown robust responses and curative potential in patients with diffuse large B-cell lymphoma, regardless of cytogenetics or age.

Itolizumab Leads to Sustained Clinical Responses in Newly Diagnosed Acute GVHD

February 16th 2021

February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

February 16th 2021

Venetoclax in Mantle Cell Lymphoma

February 16th 2021

Dr. D’Angelo on Future Directions With CAR T-Cell Therapy in Lymphoma

February 16th 2021

Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.

Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions

February 15th 2021

February 15, 2021 - Betibeglogene autotemcel, a one-time gene therapy, enabled durable transfusion independence in most patients with transfusion-dependent β-thalassemia who were treated across 4 clinical studies.

Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL

February 15th 2021

Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.

BCL2 Inhibition in AML: VIALE-A Study

February 15th 2021

Type 1/2 FLT3 Inhibitors in AML

February 15th 2021

Dr. Schiller on the Potential Utility of Asciminib in CML

February 12th 2021

Gary J. Schiller, MD, discusses the potential utility of asciminib in chronic myeloid leukemia.

Ruxolitinib Induces Improved Responses in Chronic GVHD

February 12th 2021

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

Dr. Shadman on Treatment Considerations in CLL

February 12th 2021

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

February 12th 2021

Tafasitamab Combined With Lenalidomide in R/R DLBCL

February 12th 2021